Polyrizon (PLRZ) Enterprise Value (2023 - 2025)
Polyrizon's (PLRZ) quarterly Enterprise Value came in at -$11.5 million in Q4 2025, down 349.88% YoY from $4.6 million in Q4 2024, and up 27.41% on a QoQ basis from -$15.8 million in Q2 2025.
Polyrizon (PLRZ) Enterprise Value (2023 - 2025) Analysis & Trends
Polyrizon (PLRZ) has 3 years of Enterprise Value data on file, last reported at -$11.5 million in Q4 2025.
- Quarterly Enterprise Value fell 349.88% year-over-year to -$11.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$11.5 million (down 349.88% YoY) and the FY2025 annual result came in at -$11.5 million, down 349.88% from the prior year.
- Enterprise Value rose to -$11.5 million in Q4 2025, from -$15.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$41000.0 in Q4 2023 to a low of -$15.8 million in Q2 2025.
- A 3-year average of -$7.5 million and a median of -$7.0 million in 2024 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value slumped 6129.27% — and 2025, when it tumbled 349.88%.
- Tracing PLRZ's Enterprise Value over 3 years: stood at -$41000.0 in 2023, then tumbled by 6129.27% to -$2.6 million in 2024, then slumped by 349.88% to -$11.5 million in 2025.
- The last three Enterprise Value figures came in at -$11.5 million (Q4 2025), -$15.8 million (Q2 2025), and -$2.6 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Polyrizon | 7.27 Mn | -4.22 Mn | - | -11.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -11.49 Mn |
| Jun 30, 2025 | -15.83 Mn |
| Dec 31, 2024 | -2.55 Mn |
| Dec 31, 2023 | -41,000.00 |